AbbVie Says Rinvoq Meets Endpoints in Second Phase 3 Study for Atopic Dermatitis
July 21 2020 - 9:50AM
Dow Jones News
By Michael Dabaie
AbbVie Inc. said Rinvoq, or upadacitinib, monotherapy met
primary and secondary endpoints in the second Phase 3 study in
moderate to severe atopic dermatitis.
The co-primary endpoints were at least a 75% improvement in the
Eczema Area Severity Index from baseline and a validated
Investigator's Global Assessment for Atopic Dermatitis score of
0/1--clear or almost clear--at week 16.
The Measure Up 2 study evaluates 15 mg and 30 mg doses of
upadacitinib monotherapy versus placebo in adolescents and adults
with moderate to severe atopic dermatitis.
Significantly more patients receiving either dose of
upadacitinib monotherapy showed improvement in skin clearance and
reduction in itch compared to placebo at week 16, the company
said.
Shares were up 0.4% to $99.90 premarket.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
July 21, 2020 09:35 ET (13:35 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024
